Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

fistulas

This page shows the latest fistulas news and features for those working in and with pharma, biotech and healthcare.

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline at week 16, the company outlined. ... reduction in abscess and inflammatory nodule count without an increase in abscess or draining fistula

Latest news

  • Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

    Will treat perianal fistulas in adult patients with Crohn’s disease. Takeda has chalked up a big win this week after receiving a European licence for Alofisel (darvadstrocel), marking the first ... Alofisel - previously Cx601 - is approved to treat

  • The power of pharma businesses to drive social change The power of pharma businesses to drive social change

    estimated 3, 000 new cases of obstetric fistula annually, with the problem particularly prevalent in rural communities. ... We are really proud of what we have been able to achieve with the Fistula Foundation.

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    Around a quarter of patients with Crohn’s develop fistulas - abnormal channels connecting the bowel to another organ or the outside surface of the body. ... Perianal fistulas are the most common type but are still fairly rare, with patients currently

  • CHMP backs Europe’s first allogeneic stem cell therapy CHMP backs Europe’s first allogeneic stem cell therapy

    Belgian biotech TiGenix and partner Takeda have had their stem cell therapy for perianal fistulas in Crohn’s disease patients recommended for approval in the EU. ... The most common side effects observed include anal abscess and fistula, as well as

  • TiGenix’s Crohn's fistulas treatment wins orphan drug status TiGenix’s Crohn's fistulas treatment wins orphan drug status

    FDA designation follows positive trial results. Belgian biopharmaceutical group TiGenix is one step closer to getting its first-in-class Crohn’s fistulas disease treatment to the US market following an ... The drug - currently known as Cx601 - could

More from news
Approximately 4 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease. ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead asset, allogeneic expanded adipose-derived stem cells (eASC) locally

  • Case study: Action on Fistula Case study: Action on Fistula

    fistula through building in-country capacity to recognise, treat and eventually eradicate long-term suffering. ... The programme revealed awareness of fistula is very low, even within the healthcare system.

  • Deal Watch July 2016 Deal Watch July 2016

    cells. The product has been submitted to the EMA following a phase III trial showing safety and efficacy of a single injection in the treatment of complex peri-anal fistulas, and ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment for

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Kardex

Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...

Quick links